What is William Blair's Estimate for XENE FY2027 Earnings?

Key Points

• William Blair's analyst M. Minter estimates that Xenon Pharmaceuticals will report earnings of ($5.55) per share for FY2027, with an "Outperform" rating on the stock.
• The consensus estimate for Xenon Pharmaceuticals' current full-year earnings stands at ($3.10) per share, indicating a significant projected decline in earnings.
• Xenon Pharmaceuticals' stock experienced a 2.0% increase, opening at $36.70, while the stock has a market cap of $2.82 billion.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report released on Tuesday, August 12th. William Blair analyst M. Minter expects that the biopharmaceutical company will post earnings of ($5.55) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share.

Other analysts have also issued research reports about the company. Needham & Company LLC cut their target price on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. The Goldman Sachs Group cut their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Royal Bank Of Canada dropped their price objective on Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating for the company in a research note on Tuesday. Evercore ISI assumed coverage on Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They set an "outperform" rating and a $55.00 price objective for the company. Finally, Wedbush increased their price objective on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Xenon Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $53.20.

Xenon Pharmaceuticals Stock Up 2.0%

Shares of XENE opened at $36.70 on Wednesday. The business's 50-day moving average price is $32.17 and its 200-day moving average price is $34.06. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.00. The stock has a market cap of $2.82 billion, a PE ratio of -10.38 and a beta of 1.16.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same quarter last year, the company posted ($0.75) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC acquired a new stake in Xenon Pharmaceuticals during the second quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals during the first quarter worth approximately $30,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Xenon Pharmaceuticals in the second quarter valued at approximately $32,000. GF Fund Management CO. LTD. purchased a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $63,000. Finally, Quarry LP purchased a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $78,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.